Dietary Supplements Market worth $299.57 billion by 2031- Exclusive Report by MarketsandMarkets™

MarketsandMarkets estimates the global dietary supplements market at USD 206.77 billion in 2026, projecting growth to USD 299.57 billion by 2031 at a 7.7% CAGR. It identifies vitamins as the fastest-growing type, sports nutrition as the fastest-growing function, and Asia Pacific as the fastest-growing region; the top five companies account for 35%–40% of the market. Separately, Nestlé plans to invest CHF 310 million (USD 375 million) in its Brazil nutrition and health business by 2028, including a new infant-formula facility expected to begin operations in Q2 2028.

Analysis

Treat the market forecast as a category-level narrative, not evidence of incremental earnings: it is a commercial research release, and its growth estimate does not establish listed companies’ exposure, market-share gains, or returns. The investable signal is the shift toward differentiated products, where credible clinical evidence, repeat purchase, and customer acquisition costs—not category growth alone—will determine who captures value. A proliferation of lookalike gummies, personalized offers, and wellness claims could instead raise marketing costs and invite tighter scrutiny, limiting premium margins.

Herbalife’s planned Bioniq asset purchase offers a route to personalized nutrition, but the value depends on retention, unit economics, and successful integration; the announcement is not proof of a material earnings contribution. Unilever’s Grüns acquisition adds a convenient-format brand, but do not extrapolate one deal into broad supplement-market leadership. Nestlé’s Brazil investment is primarily nutrition and infant-formula capacity, so it should not be treated as direct evidence of exposure to adult supplements.

Near term (days), this release alone is unlikely to support a durable stock move. Over 1–3 months, watch acquisition disclosures, distribution, repeat-purchase evidence, and segment commentary. Over 6–18 months, differentiated brands may benefit if they demonstrate substantiated claims and pricing power; regulatory scrutiny, weak consumer retention, or discounting could reverse that thesis. Contrarian point: projected category growth may be less valuable than the market assumes if competition and customer-acquisition spending absorb the premium.

Key Decisions for Investors

• No trade on the market forecast alone; treat it as low-conviction thematic context rather than a company-specific earnings catalyst.
• Keep Herbalife on an event-driven watchlist: reassess the Bioniq thesis when asset terms, integration costs, customer retention, and revenue contribution are disclosed. Falsify a positive view if management signals weak adoption or rising acquisition-related costs without measurable sales traction.
• For Unilever, monitor whether Grüns gains distribution and repeat purchases without materially diluting margins; do not infer a meaningful group-level growth contribution absent financial disclosure.
• Do not use Nestlé’s Brazil capacity announcement as a dietary-supplement trade catalyst: verify product scope and segment-level revenue exposure before assigning it that read-through.